Navigation Links
DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer
Date:3/13/2009

c areas, including allergy, asthma, oncology, rheumatology, hematology, diagnostics, and drug delivery systems.

"As I join the DOR team in the ongoing development of orBec(R) and the other exciting portfolio compounds, I look forward to applying my experience in drug development to my long-standing commitment to improving the lives of patients with GVHD," stated Brian L. Hamilton, MD, PhD, Chief Medical Officer of DOR.

"We are very pleased to welcome Dr. Hamilton to the DOR team," said Christopher J. Schaber, PhD, President and CEO of DOR. "We could not ask for someone whose skill set provides a better fit to lead our clinical programs forward. His experience in successfully developing Rhinocort Aqua and Pulmicort Turbuhaler (topical budesonide, the active ingredient in Entocort) while at Astra will be instrumental to us as we advance orBec(R) to Phase 3 completion in GI GVHD. His specific expertise in GVHD will be vital to the successful interaction between DOR and the Phase 3 clinical sites in our upcoming confirmatory trial. With Dr. Hamilton's demonstrated record of advancing products through clinical development to commercial success, we are enthusiastically looking forward to expeditiously completing our Phase 3 clinical trial, while continuing to expand and build our pipeline."

About DOR BioPharma, Inc.

DOR BioPharma, Inc. (DOR) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec(R) (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of GI GVHD, a common and potentially life-threatening complication of hematopoietic cell transplantation. DOR expects to begin a confirmatory Phase 3 clinical trial of orBec(R) for the treatment of acu
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
2. Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
4. XTL Biopharmaceuticals Ltd. Extraordinary General Meetings Postponed Until March 18, 2009
5. R&D Spending by U.S. Biopharmaceutical Companies Increases 3 Percent in 2008
6. Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification
7. Frost & Sullivans Biopharmaceuticals Market Briefing to Address the Use of Embryonic Stem Cells
8. Eiger BioPharmaceuticals Raises $7.1 Million A Round
9. Mindset BioPharmaceuticals (USA) Inc Obtains Notice of Allowance for European Patent Related to Use of Insulin Sensitizers in Senile Dementia, Dementia and Memory Loss
10. Mach One Closes on Acquisition of Biopharmaceutical Design & Engineering Firm
11. TechniKroms Biopharmaceutical Equipment Operations to be Integrated With Asahi Kasei Medical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Washington, USA (PRWEB) September 30, 2014 ... yet efficient arrangements that have evolved in nature over ... biomimetic and bioinspired materials for applications in biophotonics ... Biomedical Optics . The journal is published by SPIE, ... SPIE Digital Library. Several of the peer-reviewed articles are ...
(Date:10/1/2014)... 2014 Slone Partners , a ... IT, and Laboratory Testing industries, reported a 120% increase ... director level and above from July 2013 to July ... top of rapid breakthroughs in diagnostics, reimbursement has failed ... have been forced to fold, consolidate, or carry on ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 The U.S. ... to Southern Illinois University Edwardsville as part of the ... initiative. The funding is co-administered by the Department of ... Biden, Secretary of Labor Thomas E. Perez and Secretary ... million in job-driven training grants to nearly 270 colleges ...
(Date:10/1/2014)... Industry leaders from retail ... around the theme, ,Commercial Opportunities in the Era of ... Elsevier , a world-leading provider of scientific, ... a gathering of some of the industry,s most prominent ... today and in the future. The Elsevier ...
Breaking Biology Technology:Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 3Slone Partners Meets Growing Demand as Industry Focuses on Reimbursement & Regulation 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 3U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 4Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3
... Oct. 9 BioElectronics,Corporation, (Pink Sheets: BIEL), ... has cleared ActiPatch for sale by its,distributor, ... that the experienced sales professionals of,Endotherapeutics will ... team has many decades of experience in ...
... Oct. 8 SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ) ... 11,2007, at 1:00 p.m. Pacific Daylight Time. Mike Grey, ... an overview of the,Company,s oncology pipeline. The conference is ... Hotel in San Francisco. A live webcast of ...
... Inverness Medical,Innovations (Amex: IMA ) today announced ... Panbio Ltd, an Australian company traded on,the Australian Securities ... all of the issued shares in Panbio for AUD ... issued share capital of,Panbio at approximately AUD 41 million, ...
Cached Biology Technology:Australian Therapeutics Goods Administration Approval for ActiPatch Achieved 2Inverness Medical Innovations Agrees to Acquire Panbio Ltd. 2
(Date:10/1/2014)... Soil microbes that thrive in the deserts, rainforests, prairies ... living beneath New York City,s Central Park, according to ... and the University of Colorado Boulder. , The ... Central Park,s 843 acres and discovered a stunning diversity ... documented before. , Only 8.5 percent to 16.2 ...
(Date:9/30/2014)... the University of California, San Diego, have completed the ... a method that uses the pixels in an image ... as mesh-free simulation. , The researchers, led by J.S. ... the Jacobs School of Engineering at UC San Diego, ... at the CompIMAGE,14 conference in Pittsburgh this month. Chen ...
(Date:9/30/2014)... watermelon, salmon, and strawberries all have in common? ... of chromosomes and are diploid, these organisms are all ... chromosomesseedless watermelon and salmon have 3 and 4 sets ... this might seem surprising, in fact most plant species ... over a century ago, but only recently, with the ...
Breaking Biology News(10 mins):Microbes in Central Park soil: If they can make it there, they can make it anywhere 2Microbes in Central Park soil: If they can make it there, they can make it anywhere 3First comprehensive meshfree numerical simulation of skeletal muscle tissue achieved 2Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 2Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 3Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 4
... the first time, scientists at Weill Cornell Medical College in ... mechanism that,s crucial to how brain cells communicate. In ... as to how key cellular processes -- called endocytosis and ... in this week,s online edition of Proceedings of the National ...
... appear to have been influenced by RNA polymerase II. ... DNA into messenger-RNA (mRNA), which in turn is the ... is highly conserved through evolution, with many of its ... Single-cell organisms were already in existence 500 million ...
... whose mothers, sisters or daughters test positive for a cancer-causing ... disease but are unaware of that risk. That is ... exploring how families communicate genetic test results. Like their female ... in the BRCA 1 or 2 genes. Male carriers ...
Cached Biology News:Breakthrough technology observes synapse in real time, supporting theory of vesicular recycling 2Breakthrough technology observes synapse in real time, supporting theory of vesicular recycling 3Evolution with a restricted number of genes 2Men unaware of their cancer risk when female relatives test positive for BRCA mutation 2
... Special optically clear polystyrene formulation , ... immunoassay applications , Plates are certified ... of variation , Eight-well strips fit ... loss while in use even if turned ...
...
... Pierce scientists developed the Easy-Titer Human IgM ... a simple, sensitive, and easy-to-perform assay for ... an ELISA. This kit incorporates a simple ... of IgM concentration from 15-500 ng/ml in ...
... Lipid adsorption and clarification reagent; Ideal ... purification of antibodies, proteins, nucleic acids, ... negligible cross-reactivity, and improves downstream processing; ... solid-phase, non-ionic adsorbent supplied as a ...
Biology Products: